These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 2790778

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
    Watanabe M, Komeshima N, Nakajima S, Tsuruo T.
    Cancer Res; 1988 Dec 01; 48(23):6653-7. PubMed ID: 3180075
    [Abstract] [Full Text] [Related]

  • 3. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.
    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y.
    Cancer Res; 1982 Apr 01; 42(4):1462-7. PubMed ID: 7060020
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
    Fujimoto K, Oka T, Morimoto M.
    Cancer Res; 1987 Mar 15; 47(6):1516-22. PubMed ID: 2434218
    [Abstract] [Full Text] [Related]

  • 5. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Visalli M, Bisagni E, Pierré A, Atassi G.
    Cancer Chemother Pharmacol; 1996 Mar 15; 38(6):513-21. PubMed ID: 8823492
    [Abstract] [Full Text] [Related]

  • 6. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
    Shimomura K, Manda T, Mukumoto S, Masuda K, Nakamura T, Mizota T, Matsumoto S, Nishigaki F, Oku T, Mori J.
    Cancer Res; 1988 Mar 01; 48(5):1166-72. PubMed ID: 3342397
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL, Roberts BJ, Howard CT, Leopold WR.
    Cancer Res; 1994 Aug 15; 54(16):4412-8. PubMed ID: 8044790
    [Abstract] [Full Text] [Related]

  • 13. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, Kitoh K.
    Cancer Res; 1994 Apr 01; 54(7):1702-6. PubMed ID: 8137285
    [Abstract] [Full Text] [Related]

  • 14. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
    Morimoto M, Ashizawa T, Ohno H, Azuma M, Kobayashi E, Okabe M, Gomi K, Kono M, Saitoh Y, Kanda Y.
    Cancer Res; 1991 Jan 01; 51(1):110-5. PubMed ID: 1988076
    [Abstract] [Full Text] [Related]

  • 15. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
    Nakanishi O, Baba M, Saito A, Yamashita T, Sato W, Abe H, Fukazawa N, Suzuki T, Sato S, Naito M, Tsuruo T.
    Oncol Res; 1997 Jan 01; 9(2):61-9. PubMed ID: 9167187
    [Abstract] [Full Text] [Related]

  • 16. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
    Kirshenbaum MR, Chen SF, Behrens CH, Papp LM, Stafford MM, Sun JH, Behrens DL, Fredericks JR, Polkus ST, Sipple P.
    Cancer Res; 1994 Apr 15; 54(8):2199-206. PubMed ID: 8174127
    [Abstract] [Full Text] [Related]

  • 17. Preclinical antitumor activity of bizelesin in mice.
    Carter CA, Waud WR, Li LH, DeKoning TF, McGovren JP, Plowman J.
    Clin Cancer Res; 1996 Jul 15; 2(7):1143-9. PubMed ID: 9816280
    [Abstract] [Full Text] [Related]

  • 18. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
    Tsuruo T.
    Gan To Kagaku Ryoho; 1984 Mar 15; 11(3 Pt 2):750-9. PubMed ID: 6585181
    [Abstract] [Full Text] [Related]

  • 19. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N.
    Cancer Res; 1989 Aug 01; 49(15):4098-102. PubMed ID: 2472873
    [Abstract] [Full Text] [Related]

  • 20. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV, Wallace RE, Murdock KC, Angier RB, Durr FE, Forbes M.
    Cancer Res; 1982 Feb 01; 42(2):440-4. PubMed ID: 7055799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.